KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Income from Non-Controlling Interests: 2014-2015

Historic Income from Non-Controlling Interests for Jazz Pharmaceuticals (JAZZ) over the last 1 years, with Jun 2015 value amounting to -$1,000.

  • Jazz Pharmaceuticals' Income from Non-Controlling Interests rose 98.63% to -$1,000 in Q2 2015 from the same period last year, while for Jun 2015 it was $987,998, marking a year-over-year change of. This contributed to the annual value of -$1,000 for FY2015, which is 99.91% up from last year.
  • According to the latest figures from Q2 2015, Jazz Pharmaceuticals' Income from Non-Controlling Interests is -$1,000, which was down 100.09% from $1.1 million recorded in Q4 2014.
  • In the past 5 years, Jazz Pharmaceuticals' Income from Non-Controlling Interests ranged from a high of $1.1 million in Q4 2014 and a low of -$989,000 during Q1 2014.
  • Over the past 2 years, Jazz Pharmaceuticals' median Income from Non-Controlling Interests value was -$1,000 (recorded in 2015), while the average stood at -$200.30.
  • Data for Jazz Pharmaceuticals' Income from Non-Controlling Interests shows a peak YoY surged of 98.63% (in 2015) over the last 5 years.
  • Jazz Pharmaceuticals' Income from Non-Controlling Interests (Quarterly) stood at $1.1 million in 2014, then soared by 98.63% to -$1,000 in 2015.
  • Its Income from Non-Controlling Interests stands at -$1,000 for Q2 2015, versus $1.1 million for Q4 2014 and $2,000 for Q3 2014.